The degradation of PML-RARα can be induced by pharmacological doses of all-trans retinoic acid (ATRA), thereby enabling transcription and terminal differentiation of immature precursor cells.2 However, ATRA is only clinically successful for the small subset of APL patients. This evidence concerns the gene PML and acute promyelocytic leukemia.